Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas John

Showing results (321-330 of 354) with videos related to

Pageof 36
Sort By:
The Lancet. Respiratory Medicine|October 24, 2017
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion studyMyung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, et al.
Nature Medicine|March 18, 2025
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancerRoy S Herbst, Thomas John, Christian Grohé, et al.
JTO Clinical and Research Reports|September 23, 2024
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor ResistanceMalinda Itchins, Shirley Liang, Chris Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialMartin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled AnalysisSolange Peters, Luis G Paz-Ares, Martin Reck, et al.
The New England Journal of Medicine|November 22, 2019
Overall Survival with Osimertinib in Untreated, <i>EGFR</i>-Mutated Advanced NSCLCSuresh S Ramalingam, Johan Vansteenkiste, David Planchard, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2025
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutationsAdel Shahnam, Alexander Davis, Lauren Julia Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 36

Showing results (321-330 of 354) with videos related to

Sort By:
Pageof 36
The Lancet. Respiratory Medicine|October 24, 2017
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion studyMyung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, et al.
Nature Medicine|March 18, 2025
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancerRoy S Herbst, Thomas John, Christian Grohé, et al.
JTO Clinical and Research Reports|September 23, 2024
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor ResistanceMalinda Itchins, Shirley Liang, Chris Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialMartin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled AnalysisSolange Peters, Luis G Paz-Ares, Martin Reck, et al.
The New England Journal of Medicine|November 22, 2019
Overall Survival with Osimertinib in Untreated, <i>EGFR</i>-Mutated Advanced NSCLCSuresh S Ramalingam, Johan Vansteenkiste, David Planchard, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2025
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutationsAdel Shahnam, Alexander Davis, Lauren Julia Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 36